CX Institutional Makes New $31,000 Investment in Becton Dickinson and Co (NYSE:BDX)

CX Institutional bought a new position in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 124 shares of the medical instruments supplier’s stock, valued at approximately $31,000.

A number of other institutional investors have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its holdings in Becton Dickinson and by 0.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock worth $8,631,529,000 after buying an additional 131,536 shares during the last quarter. Vanguard Group Inc. raised its holdings in Becton Dickinson and by 2.3% in the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after buying an additional 520,350 shares during the last quarter. FMR LLC raised its holdings in Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares during the last quarter. Morgan Stanley raised its holdings in Becton Dickinson and by 66.7% in the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after buying an additional 1,955,095 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in Becton Dickinson and by 1.5% in the second quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock worth $824,327,000 after buying an additional 47,202 shares during the last quarter. 84.21% of the stock is owned by institutional investors and hedge funds.

Shares of BDX stock opened at $252.86 on Friday. The company has a 50 day moving average price of $253.69 and a 200-day moving average price of $245.85. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The firm has a market capitalization of $66.90 billion, a PE ratio of 22.97, a P/E/G ratio of 1.58 and a beta of 1.12. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period in the previous year, the business posted $2.91 earnings per share. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. Analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a $0.77 dividend. The ex-dividend date was Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.22%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

Several research analysts have issued reports on BDX shares. Piper Jaffray Companies decreased their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Raymond James lifted their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Co lifted their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $266.55.

In related news, Director Claire Fraser sold 1,429 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James C. Lim sold 1,929 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The disclosure for this sale can be found here. Insiders have sold 37,249 shares of company stock valued at $9,616,803 over the last 90 days. 0.12% of the stock is currently owned by company insiders.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is a Candlestick Chart?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.